Moderna Inc. ($MRNA) Stock Forecast: Down 5.3% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its mRNA platform, including the development of a COVID-19 vaccine. The stock faced notable downward movement in the market.

Why is Moderna Inc. going down?

MRNA stock is down 5.3% on Jun 5, 2026 14:36

• Moderna (MRNA) stock declined amid profit-taking following recent positive data on its personalized mRNA-based cancer vaccine.
• An individual's proposed sale of 3471 shares via an SEC filing potentially influenced the stock's downward trend.
• Despite encouraging updates on its cancer vaccine and past successful trials, investor response may have been dampened by the insider selling activity.
• The combination of profit-taking, insider selling, and general market sentiment likely contributed to Moderna's bearish performance today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Analyst Upgrades Dominion Energy (D) Following NextEra Deal Announcement

Jefferies upgraded Dominion Energy (D) from 'Hold' to 'Buy' and increased its price target to $76, representing a 14% upside. This upgrade follows the announcement of a $66.8 billion acquisition deal with NextEra Energy, which is expected to create the world's largest regulated electric utility. The analyst also cited Virginia House Bill 895, which expands renewable energy storage targets, as a factor supporting future EPS growth for Dominion Energy.

https://www.insidermonkey.com/blog/analyst-upgrades-dominion-energy-d-following-nextera-deal-announcement-1775290/

Why Is Moderna (MRNA) Stock Rocketing Higher Today

Moderna (MRNA) stock rose 5.1% after presenting positive long-term data for its personalized mRNA-based cancer vaccine, developed with Merck, at the American Society of Clinical Oncology's annual meeting. The vaccine, combined with Keytruda, showed a 49% lower risk of cancer recurrence or death in high-risk melanoma patients and a 59% reduction in distant metastasis. This news, following previous positive clinical trial results for its flu and hantavirus vaccines, reinforces confidence in Moderna's mRNA platform beyond COVID-19.

https://www.tradingview.com/news/stockstory:a11c2fe76094b:0-why-is-moderna-mrna-stock-rocketing-higher-today/

[144] Moderna, Inc. SEC Filing

This SEC filing (Form 144) for Moderna, Inc. (MRNA) indicates a proposed sale of 3471 shares by an individual. The shares were acquired through a stock option exercise on June 4, 2026, with an aggregate market value of $173,550.00 and are intended to be sold on NASDAQ via Fidelity Brokerage Services LLC. The filing shows no securities were sold in the past three months by the person.

https://www.stocktitan.net/sec-filings/MRNA/144-moderna-inc-sec-filing-2118c17d1710.html

Deutsche Bank Raises its Price Target on Star Bulk Carriers (SBLK)

Deutsche Bank has increased its price target for Star Bulk Carriers (SBLK) to $32 from $31, maintaining a Buy rating after the company's strong Q1 earnings beat. The bank cited an improving dry bulk market, a sentiment echoed by Jefferies which also initiated coverage with a Buy rating. Star Bulk Carriers reported Q1 adjusted EPS of 56 cents and revenue of $281.15 million, both exceeding consensus estimates, and declared a dividend of $0.50 per share.

https://www.insidermonkey.com/blog/deutsche-bank-raises-its-price-target-on-star-bulk-carriers-sblk-1775068/

Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

Ardelyx projects over $500 million in revenue for 2026, driven primarily by IBSRELA, its irritable bowel syndrome treatment, which is expected to bring in $410 million to $430 million. The company aims for $1 billion in IBSRELA revenue by 2029 and sees potential for profitability this year, although it is holding off on formal guidance until sustainability is confirmed. Growth strategies include an expanded sales force, enhanced prescription fulfillment via a specialty pharmacy network, and direct physician outreach.

https://finance.yahoo.com/sectors/healthcare/articles/ardelyx-eyes-500m-revenue-ibsrela-120432042.html

Trending Today

Kornit Digital Ltd. ($KRNT) Stock Forecast: Down 5.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.7% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.1% Today

Kimberly-Clark Corporation ($KMB) Stock Forecast: Up 5.6% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Down 5.1% Today

The Cooper Companies Inc. ($COO) Stock Forecast: Up 8.3% Today

Honda Motor Company Ltd. ($HMC) Stock Forecast: Down 5.0% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.0% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 5.2% Today

Patterson-UTI Energy Inc. ($PTEN) Stock Forecast: Down 5.4% Today

Moderna Inc. Price History

05.05.2026 - MRNA Stock was down 5.3%

• Moderna (MRNA) stock declined amid profit-taking following recent positive data on its personalized mRNA-based cancer vaccine.
• An individual's proposed sale of 3471 shares via an SEC filing potentially influenced the stock's downward trend.
• Despite encouraging updates on its cancer vaccine and past successful trials, investor response may have been dampened by the insider selling activity.
• The combination of profit-taking, insider selling, and general market sentiment likely contributed to Moderna's bearish performance today.

03.05.2026 - MRNA Stock was up 7.8%

• Moderna's shares surged by 8.1% today due to positive updates, including encouraging data on a new cancer vaccine, an expanded partnership for an ebolavirus vaccine, and the launch of an e-commerce platform.
• The bullish momentum was reinforced by UBS increasing its price target for Moderna, Inc. (MRNA) in anticipation of key pipeline catalysts, reflecting confidence in the company's future.
• Despite facing scrutiny over allegations regarding the efficacy of its RSV vaccine, investors appeared more focused on the positive developments and growth opportunities in the oncology market.
• Anticipated growth in the Acute Respiratory Distress Syndrome (ARDS) market and ongoing research by industry leaders likely contributed to the positive sentiment surrounding Moderna and its mRNA technology.

03.05.2026 - MRNA Stock was up 5.5%

• Moderna (MRNA) saw a significant uptrend recently due to various factors:
• Bright prospects in the Acute Respiratory Distress Syndrome (ARDS) market, with growth projections fueled by innovative therapies being researched, potentially aligning with Moderna's unique vaccine development strategies.
• Improved valuation by UBS before key pipeline events, reflecting confidence in Moderna's future and growth potential.
• Despite ongoing challenges, optimism among investors remains high regarding Moderna's upcoming projects and regulatory milestones.
• Favorable industry sentiment in healthcare, particularly in fields like oncology and acute pain management, may have influenced the positive movement in Moderna's stock.

04.05.2026 - MRNA Stock was up 9.7%

• Moderna's stock saw a 7.49% increase as investors look forward to upcoming events, such as its involvement in crucial healthcare conferences and the release of encouraging data on its melanoma treatment.
• Optimism has been reignited around Moderna's partnership with Merck for the melanoma vaccine program, showing consistent enhancements in survival rates, fueling the stock's surge.
• The President of Moderna exercising restricted stock units (RSUs), coupled with favorable updates on the company's oncology pipeline extending beyond COVID vaccines, likely bolstered bullish sentiment, propelling the stock upward today.

04.05.2026 - MRNA Stock was up 9.2%

• Moderna's stock saw a notable increase today after a period of declines, as investors are eagerly awaiting important updates from the company.
• Optimism has been reignited surrounding Moderna's collaboration with Merck on a melanoma vaccine program, with encouraging data releases contributing to the stock's upward movement.
• Investor sentiment may have been bolstered by insider activities, including the exercising of RSUs by the company's President and CFO, signaling confidence in Moderna's future growth prospects.
• Anticipation is high due to Moderna's upcoming involvement in key healthcare conferences and the unveiling of promising data related to its melanoma treatment, which has further stimulated investor interest and pushed the stock price up.

04.05.2026 - MRNA Stock was up 5.0%

• The positive outlook on Moderna's future, particularly in mRNA technology and vaccine advancements, likely drove the stock's bullish trajectory.
• A recent SEC filing suggesting a share sale by an individual may have been perceived as a routine financial action, minimally impacting the market movement.
• In contrast to Ultragenyx (RARE) facing stock declines post-disappointing earnings, Moderna's robust market performance signals strong investor confidence in its growth potential and continued success.
• Market optimism stemming from reports of Deutsche Bank's increased price target for Star Bulk Carriers (SBLK) and potential in tech stocks may have bolstered overall positive sentiment, positively influencing Moderna's stock.

29.04.2026 - MRNA Stock was up 5.1%

• Moderna's bullish movement today can be attributed to the positive sentiment surrounding its innovative mRNA technology and ongoing developments in the healthcare sector.
• The FDA advisory panel's recommendation to update COVID-19 vaccines for the XFG variant for the 2026-27 season could have boosted investor confidence in Moderna's capabilities to adapt to evolving virus strains.
• Despite insider selling and a cautious Wall Street sentiment, the potential for premium pricing and accelerated global market access for Moderna's plant-based drug targeting BPH and prostate cancer prevention could have sparked investor optimism.
• The acquisition of shares by institutional investors like Seven Grand Managers LLC further indicates confidence in Moderna's long-term growth prospects, potentially contributing to the bullish movement.

28.04.2026 - MRNA Stock was down 5.2%

• The bearish movement in Moderna's stock today can be attributed to:
• Perceived overbought conditions and technical indicators signaling reversals, leading traders to take short positions.
• Concerns about the stock being fundamentally overvalued, especially after its recent inclusion in the S&P 500 index.
• Lack of significant positive news catalysts to sustain the recent bullish momentum.
• Despite the bearish movement, the upcoming FDA advisory committee review for Moderna's mRNA flu shot and the company's preparations for a COVID-19 booster vaccine targeting the XFG strain in 2026–27 could potentially drive positive sentiment and future price movements.

20.04.2026 - MRNA Stock was up 5.1%

• Moderna's stock surged by 20% due to emerging hantavirus cases, showcasing the market's confidence in the company's pandemic defense capabilities.
• The hantavirus scare not only boosted Moderna's stock but also highlighted the potential changes in vaccine-related regulatory environments, which could further benefit the company.
• Despite concerns about declining sales and profitability, Moderna's focus on infectious disease platforms and potential vaccine developments seems to have overshadowed these worries, driving the bullish movement in its stock today.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement despite being ranked #1 on a list of Most Impactful Companies, showcasing its significant contributions to mRNA technology and public health.
• The company's Q1 earnings report with an EPS of ($3.40) may have contributed to the drop in share price, signaling potential investor concerns about profitability.
• Investors viewing Moderna as a pandemic hedge amidst reduced demand for Covid vaccines and regulatory challenges might have led to conflicting sentiments and added to the stock's volatility.
• The overall market sentiment towards biotech companies and vaccine manufacturers could have influenced Moderna's stock movement, with investors closely monitoring developments in the healthcare sector.

19.04.2026 - MRNA Stock was down 5.1%

• Moderna's bearish movement today may be linked to an insider sale by President Stephen Hoge, potentially unsettling investors and adding to stock volatility.
• The market sentiment around mRNA technology and the company's need to stabilize revenue post-pandemic could be contributing to the downward trend, despite positive growth from international partnerships and new vaccines.
• Investors may also be reacting to potential legal risks from intellectual property disputes, as mentioned in a recent conference audio transcript, which might be impacting Moderna's stock performance.
• The company's strong clinical and regulatory progress, beneficial for its long-term prospects, may not be sufficient to counter the immediate market factors influencing today's bearish movement.

19.04.2026 - MRNA Stock was down 6.9%

• Moderna's stock faced a downward trend subsequent to an insider selling 53,336 shares, conducted by President Stephen Hoge. This transaction heightened stock volatility, indicating investor sensitivity to internal activities.
• The market's adverse response to the insider sale potentially reflects uncertainties about Moderna's future growth trajectory and stability post-pandemic.
• Investor focus remains on Moderna's vaccine demand, progress in pipeline projects, and endeavors to stabilize revenue, all pivotal in determining stock performance.
• Noteworthy advancements from Wave Life Sciences regarding its AATD trial possibly impacted the biotech sector positively, while Moderna's descent was influenced by the insider transaction.